Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Advaxis has announced the preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer.
Subscribe to our email newsletter
The Phase 2 study enrolled 87 out of a planned 110 patients to assess the safety and efficacy of ADXS-HPV with and without cisplatin (40 mg/m2) and to determine if ADXS-HPV can be safely administered in combination with platinum chemotherapy.
The primary efficacy endpoint of the ADXS-HPV trial is overall survival.
The Phase 2 trial demonstrated that percentage of patients alive at 6 months is 62%, at 9 months is 41% and at one year is 40%.
The trial showed that 34% of patients experienced a ADXS-HPV drug-related adverse event, consisting of Grade 1 or 2 events and one Grade 3 event.
ADXS-HPV drug is now being evaluated in four Phase 2 clinical trials for HPV-associated diseases.